Amyloid binding agents

Abstract

There are provided compounds and methods for the detection of amyloids and treatment of diseases related to amyloids including Alzheimer's disease and other related amyloid-based neurodegenerative diseases.

1 - 16 . (canceled) 
     
     
         17 . A method of treating a disease characterized by an accumulation of an amyloid peptide in a subject, comprising administering to a subject in need of treatment an effective amount of a compound or pharmaceutical composition having the structure of formula (I): 
       
         
           
           
               
               
           
         
         wherein 
         EDG is an electron donor group; 
         πCE is a pi-conjugation element; and 
         WSG is a water soluble group; 
         wherein 
         said EDG is R 1 -substituted or unsubstituted alkyl, R 1 -substituted or unsubstituted cycloalkyl, R 1 -substituted or unsubstituted heteroalkyl, R 1 -substituted or unsubstituted heterocycloalkyl, R 1 -substituted or unsubstituted aryl, R 1 -substituted or unsubstituted heteroaryl, OR 2 —NR 4 C(O)R 3 , —NR 4 R 5 , —SR 6 , or —PR 7 R 8 , 
         wherein 
         R 1  is independently halogen, —OR 9 , —NR 10 R 11 , unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl; 
         R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8  are independently hydrogen, R 12 -substituted or unsubstituted alkyl, R 12 -substituted or unsubstituted heteroalkyl, R 12 -substituted or unsubstituted cycloalkyl, R 12 -substituted or unsubstituted heterocycloalkyl, R 12 -substituted or unsubstituted aryl or R 12 -substituted or unsubstituted heteroaryl, wherein R 4  and R 5  are optionally joined together to form an R 12 -substituted or unsubstituted heterocycloalkyl, or R 12 -substituted or unsubstituted heteroaryl; 
         R 9 , R 10 , and R 11  are independently hydrogen, R 12 -substituted or unsubstituted alkyl, R 12 -substituted or unsubstituted heteroalkyl, R 12 -substituted or unsubstituted cycloalkyl, R 12 -substituted or unsubstituted heterocycloalkyl, R 12 -substituted or unsubstituted aryl, or R 12 -substituted or unsubstituted heteroaryl, wherein R 10  and R 11  are optionally joined together to form an R 12 -substituted or unsubstituted heterocycloalkyl, or R 12 -substituted or unsubstituted heteroaryl; 
         R 12  is independently halogen, —OR 13 , —NR 14 R 15 , R 16 -substituted or unsubstituted alkyl, R 16 -substituted or unsubstituted heteroalkyl, R 16 -substituted or unsubstituted cycloalkyl, R 16 -substituted or unsubstituted heterocycloalkyl, R 16 -substituted or unsubstituted aryl, or R 16 -substituted or unsubstituted heteroaryl; 
         R 13 , R 14 , and R 15  are independently hydrogen or unsubstituted alkyl; and R 16  is independently unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl; wherein said pi-conjugation element has the formula:
   -L 1 -(A 1 ) q -L 2 -(A 2 ) r -L 3 - or -L 1 -(A 1 ) q -L 4 -A 3 -L 2 -(A 2 ) r -L 3 -, 
 
         wherein 
         q and r are independently 0 or 1 and at least one of q or r is 1; 
         A 1  A 2 , and A 3  are independently R 17 -substituted or unsubstituted arylene or R 17 -substituted or unsubstituted heteroarylene; 
         L 1 , L 2 , L 3 , and L 4  are independently a bond or a linking group having the formula: 
       
       
         
           
           
               
               
           
         
          wherein x is an integer from 1 to 50; 
         R 17  is independently halogen, —OR 18 , —NR 19 R 20 , R 21 -substituted or unsubstituted alkyl, R 21 -substituted or unsubstituted heteroalkyl, R 21 -substituted or unsubstituted cycloalkyl, R 21 -substituted or unsubstituted heterocycloalkyl, R 21 -substituted or unsubstituted aryl, or R 21 -substituted or unsubstituted heteroaryl; 
         R 18 , R 19 , and R 20  are independently hydrogen, R 21 -substituted or unsubstituted alkyl, R 21 -substituted or unsubstituted heteroalkyl, R 21 -substituted or unsubstituted cycloalkyl, R 21 -substituted or unsubstituted heterocycloalkyl, R 21 -substituted or unsubstituted aryl, or R 21 -substituted or unsubstituted heteroaryl; 
         R 21  is independently halogen, —OR 22 , —NR 23 R 24 , unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl; and 
         R 22 , R 23 , and R 24  are independently hydrogen or unsubstituted alkyl; and 
         wherein said water soluble group is R 25 -substituted or unsubstituted alkyl, R 25 -substituted or unsubstituted heteroalkyl, R 25 -substituted or unsubstituted cycloalkyl, R 25 -substituted or unsubstituted heterocycloalkyl, R 25 -substituted or unsubstituted aryl, R 25 -substituted or unsubstituted heteroaryl; wherein R 25  is independently halogen, —OR 26 , —NR 27 R 28 , R 29 -substituted or unsubstituted alkyl, R 29 -substituted or unsubstituted heteroalkyl, R 29 -substituted or unsubstituted cycloalkyl, R 29 -substituted or unsubstituted heterocycloalkyl, R 29 -substituted or unsubstituted aryl, or R 29 -substituted or unsubstituted heteroaryl; R 26 , R 27 , and R 28  are independently hydrogen, R 29 -substituted or unsubstituted alkyl, R 29 -substituted or unsubstituted heteroalkyl, R 29 -substituted or unsubstituted cycloalkyl, R 29 -substituted or unsubstituted heterocycloalkyl, R 29 -substituted or unsubstituted aryl, or R 29 -substituted or unsubstituted heteroaryl, wherein R 27  and R 28  are optionally joined together to form an R 29 -substituted or unsubstituted heterocycloalkyl, or R 29 -substituted or unsubstituted heteroaryl; 
         R 29  is independently halogen, —OR 30 , —NR 31 R 32 , unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl; and R 30 , R 31 , and R 32  are independently hydrogen or unsubstituted alkyl. 
       
     
     
         18 . The method of  claim 17 , wherein at least one of A 1  or A 2  is independently R 17 -substituted or unsubstituted 
       
         
           
           
               
               
           
         
       
     
     
         19 . The method of  claim 17 , wherein x is an integer from 1 to 10. 
     
     
         20 . The method of  claim 17 , wherein said water soluble group is an ethylene glycol moiety having the formula: 
       
         
           
           
               
               
           
         
         wherein y is an integer from 1 to 50. 
       
     
     
         21 . The method according to  claim 20 , wherein R 29  is independently unsubstituted alkyl. 
     
     
         22 . The method according to  claim 17 , wherein said compound has the structure: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         23 . The method of  claim 17 , wherein said amyloid peptide is AP peptide, prion, protein, α-synuclein, or superoxide dismutase. 
     
     
         24 . The method of  claim 23 , wherein said amyloid peptide forms part of an amyloid. 
     
     
         25 . The method of  claim 17 , wherein said compound has the structure: 
       
         
           
           
               
               
           
         
       
     
     
         26 . A method of treating a disease characterized by an accumulation of amyloids in a subject, comprising:
 i) contacting, in a subject in need of treatment, an amyloid peptide with an effective amount of a compound or pharmaceutical composition having the structure of formula (IVa) or formula (IVb), or a pharmaceutically acceptable salt thereof; and   ii) detecting said detectable amyloid complex;   wherein formula (IVa) has the structure:   
       
         
           
           
               
               
           
         
          and 
         wherein formula (IVb) has the structure: 
       
       
         
           
           
               
               
           
         
         wherein R 4  and R 5  are independently hydrogen, R 12 -substituted or unsubstituted alkyl, R 12 -substituted or unsubstituted heteroalkyl, R 12 -substituted or unsubstituted cycloalkyl, R 12 -substituted or unsubstituted heterocycloalkyl, R 12 -substituted or unsubstituted aryl or R 12 -substituted or unsubstituted heteroaryl, wherein R 4  and R 5  are optionally joined together to form an R 12 -substituted or unsubstituted heterocycloalkyl, or R 12 -substituted or unsubstituted heteroaryl; 
         R 12  is independently halogen, —OR 13 , —NR 14 R 15 , R 16 -substituted or unsubstituted alkyl, R 16 -substituted or unsubstituted heteroalkyl, R 16 -substituted or unsubstituted cycloalkyl, R 16 -substituted or unsubstituted heterocycloalkyl, R 16 -substituted or unsubstituted aryl, or R 16 -substituted or unsubstituted heteroaryl; 
         R 13 , R 14 , and R 15  are independently hydrogen or unsubstituted alkyl; 
         R 16  is independently unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl; 
         R 17  is independently halogen, —OR 18 , —NR 19 R 20 , R 21 -substituted or unsubstituted alkyl, R 21 -substituted or unsubstituted heteroalkyl, R 21 -substituted or unsubstituted cycloalkyl, R 21 -substituted or unsubstituted heterocycloalkyl, R 21 -substituted or unsubstituted aryl, or R 21 -substituted or unsubstituted heteroaryl; 
         R 18 , R 19 , and R 20  are independently hydrogen, R 21 -substituted or unsubstituted alkyl, R 21 -substituted or unsubstituted heteroalkyl, R 21 -substituted or unsubstituted cycloalkyl, R 21 -substituted or unsubstituted heterocycloalkyl, R 21 -substituted or unsubstituted aryl, or R 21 -substituted or unsubstituted heteroaryl; 
         R 21  is independently halogen, —OR 22 , —NR 23 R 24 , unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl; 
         R 22 , R 23 , and R 24  are independently hydrogen or unsubstituted alkyl; 
         R 29  is independently halogen, —OR 30 , —NR 31 R 32 , unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl; 
         R 30 , R 31 , and R 32  are independently hydrogen or unsubstituted alkyl; 
         y is an integer from 1 to 10; and 
         z is an integer from 0 to 4 when the amyloid peptide is contacted with a compound having the structure of formula IVa, and is an integer from 0 to 6 when the amyloid peptide is contacted with a compound having the structure of formula IVb. 
       
     
     
         27 . The method of  claim 26 , wherein said compound has the structure: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         28 . The method of  claim 26 , wherein R 4  and R 5  are optionally joined together to form an R 12 -substituted or unsubstituted heterocycloalkyl. 
     
     
         29 . The method of  claim 26 , wherein said R 12 -substituted or unsubstituted heterocycloalkyl is substituted or unsubstituted piperidinyl. 
     
     
         30 . The method of  claim 26 , wherein y is 2 and z is 0. 
     
     
         31 . The method of  claim 26 , wherein said compound has the structure: